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Abstract
Background: The impact of obesity on the prognosis of hepatocellular carcinoma (HCC) has not been well
characterized in a Chinese population. Therefore, the aim of this study was to examine the influence of BMI on the
clinicopathological characteristics and mortality of patients with HCC.
Methods: The study cohort consisted of 379 patients who were diagnosed with HCC at the First Affiliated Hospital
of Harbin Medical University between June 2012 and August 2014. Study subjects were divided into two body
mass index (BMI) categories: normal weight (BMI <23 kg/m2) and overweight (BMI ≥23 kg/m2).
Results: Of the 379 patients, 44 (11.6 %) were underweight (<18.5 kg/m2), 172 (45.4 %) had a normal weight
(18.5 ≤ BMI < 23.0), 133 (35.1 %) were overweight (23.0 ≤ BMI < 27.5), and 30 (7.9 %) were obese (BMI ≥27.5). After a
median follow-up time of 296 (range, 15–720) days, 168 (44.3 %) patients died with median survival time of 159
(range, 15–690) days. Patients with lower BMIs also exhibited a higher liver-related mortality rate (60.6 vs. 22.7 %;
p = 1.8 × 10−13) and a shorter survival time (353 days vs. 571 days; p = 6.2 × 10−6) than patients with higher BMIs. In
multivariate analysis, the BMI class was also found to be a significant independent impact factor for overall survival
(p = 2.2 × 10−8), age, alpha-fetoprotein level, Child–Pugh score, treatment strategy, antiviral treatment, extrahepatic
metastasis, and tumor infiltration of the portal vein.
Conclusions: Our data suggest that lower BMI has a significant impact regarding poor outcomes in patients with
HCC. To better understand the impact of BMI on the prognosis of HCC patients, more large-scale cohort studies will
be necessary.
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Background
Hepatocellular carcinoma (HCC) is a major global health
burden and is the fifth most commonly diagnosed can-
cer in the world [1]. Its incidence and mortality have
largely reflected the prevalence of hepatitis B (HBV) and
C (HCV) viral infections, particularly in China. Recently,
obesity has been found to be related to a variety of cancers
including pancreatic cancer, colorectal cancer, and esopha-
geal cancer [2–4]. Epidemiological data has shown that
obesity not only increases the risk and progression of both
HBV- and HCV-associated cirrhosis and HCC, but also is
associated with non-B non-C HCC [5]. Moreover, the im-
pact of obesity on the prognosis of HCC has not been well
characterized in Chinese populations. Consequently, in
the present study, we explored the significance of body
mass index (BMI)-defined obesity on the survival of HCC
patients in a Chinese population.
Methods
Patients
A total of 379 patients with liver cirrhosis diagnosed his-
tologically or by typical clinical signs, diagnosed with
HCC at the First Hospital of Harbin Medical University
between June 2012 and August 2014, were studied
retrospectively. A diagnosis of HCC was based on typ-
ical CT findings, namely hyperattenuation in the arterial
phase and hypoattenuation in the equilibrium phase.
HCC stages were classified according to the Barcelona
Clinic Liver Cancer (BCLC) staging system [6]. Patients
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with a previous cancer history and those suspected of
having metastatic hepatic cancer were excluded from
our study. Written consent was obtained from each of
our patients. The study was approved by the local ethics
committee of the First Hospital of Harbin Medical
University.
Data collection
We recorded the following clinical data upon first ad-
mission and diagnosis in our department: age; sex; BMI;
smoking and alcohol consumption history (ever or never);
presence of diabetes mellitus; hepatitis infection status
(HBV, HCV, HBV + HCV or none); Child–Pugh classifica-
tion; BCLC stage; history of previous hepatitis treatment;
and alpha-fetoprotein (AFP) level. Body weight was mea-
sured on admission. BMI was calculated as weight divided
by height squared (kg/m2). According to the WHO clas-
sification for Asian populations, the patients were cate-
gorized as underweight (BMI <18.5), normal weight
(18.5 ≤ BMI < 23.0), overweight (23.0 ≤ BMI < 27.5), and
obese (BMI ≥27.5) [7]. Because the number of patients
in the underweight group and the obese group was
Table 1 Baseline characteristics of study patients according to BMI
Characteristic All cases Normal weight (BMI <23 kg/m2) Overweight (BMI ≥23 kg/m2) p value
No. of patients 379 (100 %) 216 (57.0 %) 163 (43.0 %)
Age, years 63.4 ± 11.7 64.0 ± 11.5 62.6 ± 11.8 0.199
Gender, male 219 (57.6 %) 116 (53.0 %) 103 (47.0 %) 0.064
Diabetes 71 (18.7 %) 35 (49.3 %) 36 (50.7 %) 0.147
Alcohol 95 (25.1 %) 54 (56.8 %) 41 (43.2 %) 0.973
Smoking 120 (31.7 %) 74 (61.7 %) 46 (38.3 %) 0.211
AFP ≥400 μg/L 228 (60.2 %) 71 (31.1 %) 157 (68.9 %) 0.760
Viral status 0.691
HBV 237 (62.5 %) 134 (56.5 %) 103 (43.5 %)
HCV 125 (33.0 %) 70 (56 %) 55 (44 %)
HBV + HCV 1 (0.3 %) 1 (100 %) 0 (0 %)
None 16 (4.2 %) 11 (68.8 %) 5 (31.2 %)
Previous treatment 0.717
Yes 113 (31.1 %) 66 (58.4 %) 47 (41.6 %)
No 250 (68.9 %) 139 (55.6 %) 111 (44.4 %)
Child–Pugh class 2.7 × 10−4
A 99 (26.1 %) 44 (44.4 %) 55 (55.6 %)
B 107 (28.2 %) 57 (53.3 %) 50 (46.7 %)
C 173 (45.6 %) 115 (66.5 %) 58 (33.5 %)
Extrahepatic metastasis 0.113
Yes 36 (9.5 %) 25 (69.4 %) 11 (30.6 %)
No 343 (90.5 %) 191 (55.7 %) 152 (44.3 %)
Infiltration of portal vein 0.304
Yes 139 (36.7 %) 84 (60.4 %) 55 (39.6 %)
No 240 (63.3 %) 132 (55.0 %) 108 (45.0 %)
Treatment after diagnosis 1.3 × 10−4
Yes 151 (39.8 %) 68 (45.0 %) 83 (55.0 %)
No 228 (60.2 %) 148 (64.9 %) 80 (35.1 %)
BCLC stage 8.2 × 10−5
0 stage 10 (2.6 %) 3 (30.0 %) 7 (70.0 %)
1 stage 64 (16.9 %) 28 (43.8 %) 36 (56.2 %)
2 stage 78 (20.6 %) 38 (48.7 %) 40 (51.3 %)
3 stage 54 (14.2 %) 32 (59.3 %) 22 (40.7 %)
4 stage 173 (45.6 %) 115 (66.5 %) 58 (33.5 %)
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small, we divided all patients into two groups based on
a BMI above or below 23.0 [8].
Statistical analysis
All statistical analyses were carried out using SPSS ver-
sion 17 (SPSS Inc. Chicago Illinois, USA) software. Dif-
ferences in clinical features were assessed using the
chi-square and Mann–Whitney U tests and ANOVA
for continuous variables. A survival analysis was per-
formed using the Kaplan–Meier procedure and com-




Of the 379 eligible patients, 44 (11.6 %) were under-
weight (<18.5 kg/m2), 172 (45.4 %) had a normal weight
(18.5 ≤ BMI < 23.0), 133 (35.1 %) were overweight
(23.0 ≤ BMI < 27.5), and 30 (7.9 %) were obese (BMI ≥27.5).
The median BMI of the entire cohort was 22.6 (14.8–34.1).
Two hundred and sixteen (57.0 %) patients were in-
cluded in the normal weight group (BMI <23.0) and
163 (43.0 %) in the overweight group (BMI ≥23.0).
Baseline characteristics and clinicopathological fea-
tures are detailed in Table 1.
Mean patient age was 63.4 ± 11.7 years. HBV (62.5 %)
infection was more prevalent than HCV in our cohort.
After admission, 39.8 % of patients (151 cases) received
surgery and/or transarterial chemoembolization treat-
ment. The BCLC stage distribution was as follows: stage
0, 10 (12.6 %); stage A, 64 (16.9 %); stage B, 78 (20.6 %);
stage C, 54 (14.2 %); and stage D, 173 (45.6 %). Other
baseline characteristics are detailed in Table 1.
Association of BMI with clinicopathologic variables
We examined the association between the categorical
BMI and clinicopathologic variables (Table 1). In patients
with advanced Child–Pugh scores and BCLC stages a
trend towards lower weight was observed (p = 2.7 × 10−4
and p = 8.2 × 10−5, respectively). Of the 379 HCC patients,
52 (13.7 %) had undergone surgical therapy and 116
(30.6 %) had received TACE treatment, including 17
who had received surgery as well as TACE. As
Table 2 Overall survival for various characteristics based on
Kaplan–Meier analysis
Variables Overall survival (d)
mean (95 % CI)
p
BMI 3.6 × 10−13
<23 kg/m2 353.9 (316.9–391.0)
≥23 kg/m2 571.8 (532.3–611.4)
Age 0.924
<60 years 444.9 (397.6–492.1)














≥400 μg/L 456.8 (405.2–508.4)







Child–Pugh class 3.6 × 10−31
A class 627.1 (592.0–662.2)
B class 479.7 (435.0–524.5)
C class 232.0 (198.9–265.2)
Extrahepatic metastasis 5.3 × 10−13
Yes 202.4 (148.4–256.4)
No 471.2 (440.7–501.7)
Infiltration of portal vein 1.4 × 10−13
Yes 259.9 (228.0–290.8)
No 513.2 (479.2–547.1)
Treatment after diagnosis 2.5 × 10–31
Yes 617.2 (589.2–645.2)
No 259.7 (232.5–286.9)
Table 2 Overall survival for various characteristics based on
Kaplan–Meier analysis (Continued)
BCLC stage 1.4 × 10−36
0 stage 696.3 (652.7–739.8)
1 stage 678.8 (653.2–704.4)
2 stage 544.8 (500.2–589.4)
3 stage 299.6 (257.9–341.2)
4 stage 232.0 (198.9–265.2)
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detailed in Table 1, HCC patients who had undergone
curative treatment had a tendency towards higher
BMIs (p = 1.3 × 10−4).
Impact of BMI on the prognosis of patients with HCC
After a median follow-up time of 296 (range, 15–720)
days, 168 (44.3 %) patients had died with a median sur-
vival time of 159 (range, 15–690) days. Univariate ana-
lysis revealed that categorical Child–Pugh score and
BCLC stage were significantly associated with overall-
survival time. In particular, patients with higher Child–
Pugh scores and BCLC stages had significantly shorter
overall survival times as compared with lower-category
patients (p = 3.6 × 10−31 and p = 1.4 × 10−36, respectively;
Table 2). Similarly, median overall survival was shorter
in patients with distant metastasis and infiltration of the
portal vein (Table 2). Patients with HCC who received
surgery and/or TACE treatment had a better clinical
outcome (p = 2.5 × 10−31; Table 2). In addition, patients
with a lower BMI also exhibited a higher liver-related
mortality rate (60.6 vs. 22.7 %; p = 1.8 × 10−13; Table 2) and
shorter survival time (353 vs. 571 days; p = 6.2 × 10−6) than
patients with a higher BMI; this suggested that the BMI
was a complementary predictor of poor prognosis in pa-
tients with HCC. As shown in Fig. 1, we found that pa-
tients with a higher BMI tended to have a longer overall
survival (p = 3.6 × 10−13; Table 2).
We performed multivariate analysis to identify factors
that were independently associated with all-cause mor-
tality. In multivariate analysis, BMI class was also found
to be a significant independent impact factor regarding
overall survival (p = 2.2 × 10−8), age, AFP, Child–Pugh
score, treatment strategy, antiviral treatment, extrahepatic
metastasis, and tumor infiltration of the portal vein
(Table 3).
Discussion
Worldwide, the incidence of individuals with excessive
body weight or obesity has increased markedly over the
past decades. BMI has long been considered an import-
ant factor in predicting the prognostic outcome in pa-
tients with many types of cancer including colon,
pancreatic, and esophageal. In HCC, the results of lim-
ited studies regarding the influence of obesity on treat-
ment outcome are unclear. For instance, a high BMI is
well established as a prognostic factor for poor survival.
In a study that included 328 consecutive patients with
primary HCC and 60 patients with recurrent HCC, pa-
tients in the obese group were reported to exhibit sig-
nificantly poorer long-term prognosis than those in the
non-obese group [9]. In contrast, a study by Okamura et
al. reported that a low BMI was a significant prognostic
factor for low overall survival after hepatectomy for
HCC [10]. These discrepancies may have resulted from
the difference in BMI category between the two study
Fig. 1 Relationship between BMI and prognosis of patients with HCC. Kaplan-Meier survival analysis demonstrating low BMI was significantly
related to poor prognosis
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populations. In the latter study [10], the subjects were
divided using a BMI of 18.5; patients with a low BMI of
< 18.5 were commonly in a more vulnerable immuno-
logical state and had a higher frequency of more malig-
nant HCC.
Several factors have been identified that influence the
outcome of patients with HCC. Number and size of hep-
atic tumors, portal infiltration, metastasis, Child–Pugh
score, and treatment algorithm are established impact
factors regarding the survival of HCC patients [6, 11].
Malnutrition is a factor that has an important nega-
tive influence on the clinical performance status of
patients with liver cirrhosis in addition to malignant
disease. Merli et al. found that patients with impaired
nutritional status did less well concerning liver trans-
plantation [12]. In our study, we found that patients
with a higher BMI had lower rates of liver-related
mortality relative to patients with a lower BMI. More-
over, patients with a higher BMI showed a trend to-
wards better overall survival in multivariate analysis.
Therefore, BMI may be linked to the nutritional sta-
tus of HCC patients and influence the prognostic
outcome.
BMI is a simple measurement based on individual
weight and height, and is widely used. However, some
investigators have identified that calculation of the BMI
is not suitable for the identification of malnourished pa-
tients with HCC, and that differences in body compos-
ition rather than in BMI may be a true determinant of
prognosis. In this regard, Fujiwara et al. measured the
skeletal muscle index, mean muscle attenuation, visceral
adipose tissue index, subcutaneous adipose tissue index,
and visceral-to-subcutaneous adipose tissue area ratios
using CT rather than the BMI endpoint. They concluded
that sarcopenia, intramuscular fat deposition, and vis-
ceral adiposity can independently predict mortality in
patients with HCC [13]. However, these measurements
are anthropometrically more difficult in clinical practice
as compared with the BMI. In addition, nutritional
status and body composition assessed using the BMI are
relatively less precise in liver cirrhosis patients with
HCC, in light of the fact that ascetic status could be
overestimated in the calculation of BMI. However, mal-
nutrition is the sole impact factor that affects the BMI,
and ascites have only a limited effect on the BMI. Fur-
thermore, ascites are one of the important components
in the determination of the Child–Pugh score. Our study
revealed clear evidence that a higher BMI is associated
with better prognosis, although a high Child–Pugh score
adversely affected HCC outcome. This suggests that
BMI is an appropriate factor in the evaluation of nutri-
tional status, despite its limitations.
Our study was the first to focus on BMI with regard to
the prognosis of patients with HCC. However, it had
some limitations. First, there was bias because it was a
retrospective study. Second, CT data were not available
for our patients, and only BMI was evaluated rather than
body composition components.
Conclusions
In conclusion, our data suggest that a lower BMI has a
significant impact regarding the poor treatment out-
comes of patients with HCC. To better understand the
impact of BMI on the prognosis of HCC patients, more
large-scale cohort studies will be required.
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